Literature DB >> 29419428

Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.

Peter Hillmen1, Joris Diels2, Nollaig Healy3, Wafae Iraqi4, Johan Aschan5, Mark Wildgust6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29419428      PMCID： PMC5927988          DOI： 10.3324/haematol.2017.178798

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Authors:  Asher Chanan-Khan; Paula Cramer; Fatih Demirkan; Graeme Fraser; Rodrigo Santucci Silva; Sebastian Grosicki; Aleksander Pristupa; Ann Janssens; Jiri Mayer; Nancy L Bartlett; Marie-Sarah Dilhuydy; Halyna Pylypenko; Javier Loscertales; Abraham Avigdor; Simon Rule; Diego Villa; Olga Samoilova; Panagiots Panagiotidis; Andre Goy; Anthony Mato; Miguel A Pavlovsky; Claes Karlsson; Michelle Mahler; Mariya Salman; Steven Sun; Charles Phelps; Sriram Balasubramanian; Angela Howes; Michael Hallek
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

2.  Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge.

Authors:  Richard L Schilsky
Journal:  J Am Coll Surg       Date:  2016-10-28       Impact factor: 6.113

3.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

4.  Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.

Authors: 
Journal:  Haematologica       Date:  2016-10-18       Impact factor: 9.941

Review 5.  Ibrutinib: first global approval.

Authors:  Fiona Cameron; Mark Sanford
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 6.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

7.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  9 in total
  3 in total

1.  Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51.

Authors:  Ya Zhang; Xin Wang; Yang Han; Xinting Hu; Xiaoya Yun; Jiarui Liu; Juan Yang; Zheng Tian; Xin Zhang
Journal:  Cell Death Dis       Date:  2021-11-15       Impact factor: 8.469

2.  Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.

Authors:  John F Seymour
Journal:  Blood Adv       Date:  2022-02-22

3.  Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.

Authors:  Gilles Salles; Emmanuel Bachy; Lukas Smolej; Martin Simkovic; Lucile Baseggio; Anna Panovska; Hervé Besson; Nollaig Healy; Jamie Garside; Wafae Iraqi; Joris Diels; Corinna Pick-Lauer; Martin Spacek; Renata Urbanova; Daniel Lysak; Ruben Hermans; Jessica Lundbom; Evelyne Callet-Bauchu; Michael Doubek
Journal:  Ann Hematol       Date:  2019-11-19       Impact factor: 3.673
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.